Fig. 5From: The potential of deferasirox as a novel therapeutic modality in gastric cancerMolecular mechanisms of synergistic effect. Western blot analysis was performed with lysates of AGS cells treated with deferasirox (5 μM), cisplatin (5 μM), or both for 24 h. The combination of deferasirox and cisplatin induced the upregulation of NDRG1, p21, and p53, in addition to the downregulation of phospho-mTOR, ferroportin, and pro-caspase 9Back to article page